Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer

EP: 3.HER2+ Breast Cancer: Anthracycline Considerations

EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends

EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer

EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer

EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer

Now Viewing

EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights

EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges

EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer

EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

O’Shaughnessy and Rugo discuss the management of HER2-positive breast cancer with brain metastases, highlighting the impact of the HER2CLIMB trial on treatment decisions. Rugo emphasizes the survival advantage observed in patients with active brain metastases, particularly with the tucatinib regimen, as demonstrated in the trial. The discussion delves into the challenges of treating patients with asymptomatic brain metastases and the evolving role of surveillance brain MRIs. Rugo sheds light on a flatiron database analysis, showcasing the cumulative incidence of brain metastases over time in patients with HER2-positive breast cancer. The findings reveal that by the third line of therapy, almost all patients with HER2-positive disease prone to brain metastases have developed them. This early occurrence differs from other breast cancer subtypes. The discussion underscores the complexities of treating brain metastases and the need for tailored approaches based on evolving evidence.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.